Johnson & Johnson shares fell as much as 6.8% despite an improved full-year earnings outlook. A sharp decline in reported quarterly profit, weaker-than-expected MedTech performance and litigation-related charges weighed on investor sentiment despite revenue growth and adjusted earnings beating estimates.
Johnson & Johnson shares fell as much as 6.8% despite an improved full-year earnings outlook. A sharp decline in reported quarterly profit, weaker-than-expected MedTech performance and litigation-related charges weighed on investor sentiment despite revenue growth and adjusted earnings beating estimates.
<iframe src="https://hindustansphere.com/embed/cluster/b86bba5d88a27a7e56473aa6ed0013e54628c5db" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Johnson & Johnson stock rout: What's driving the sharp decline?"></iframe>
